Suppr超能文献

一项为期10周的体重控制计划对精神分裂症或分裂情感性障碍肥胖患者的影响:12个月随访

Effects of a 10-week weight control program on obese patients with schizophrenia or schizoaffective disorder: a 12-month follow up.

作者信息

Chen Chih-Ken, Chen Yi-Chih, Huang Yu-Shu

机构信息

Department of Psychiatry, Chang Gung Memorial Hospital, Keelung, Taiwan.

出版信息

Psychiatry Clin Neurosci. 2009 Feb;63(1):17-22. doi: 10.1111/j.1440-1819.2008.01886.x. Epub 2008 Dec 1.

Abstract

AIMS

Weight gain secondary to antipsychotic medication is associated with many serious conditions, including type II diabetes mellitus, hypertension, and coronary heart disease, and also with poor medication compliance. Weight control programs may be of benefit to outpatients with schizophrenia, but also raise an issue of cost-effectiveness. We aimed to evaluate the effectiveness of a 10-week weight control program for outpatients taking atypical antipsychotics for treatment of schizophrenia, and to follow up the effects of this weight control program in controlling weight gain after termination of the program.

METHODS

A total of 33 patients with schizophrenia and antipsychotic-related obesity were enrolled in a 10-week multimodal weight control program. The patients' weights were recorded at baseline, week 4, week 8, week 10 (end of the intervention), week 12, week 24, and week 48. Secondary measures included blood sugar levels, cholesterol levels, triglyceride levels, quality of life and mental health.

RESULTS

For those who completed the weight control program, there was a mean weight loss of 2.1 kg by the end of the intervention, 3.7 kg over 6 months, and 2.7 kg over 12 months. The mean body mass index decreased by 0.8, 1.5 and 1.1 at week 10, week 24 and week 48, respectively, all with statistical significance.

CONCLUSIONS

The 10-week weight control program was effective in terms of weight reduction among obese patients with schizophrenia or schizoaffective disorder, and the weight reduction effect lasted for up to 6 months, and up to 12 months in some cases.

摘要

目的

抗精神病药物导致的体重增加与许多严重疾病相关,包括2型糖尿病、高血压和冠心病,还与药物依从性差有关。体重控制项目可能对精神分裂症门诊患者有益,但也引发了成本效益问题。我们旨在评估一项为期10周的体重控制项目对服用非典型抗精神病药物治疗精神分裂症的门诊患者的有效性,并在该项目结束后随访该体重控制项目在控制体重增加方面的效果。

方法

共有33例患有精神分裂症且因抗精神病药物导致肥胖的患者参加了一项为期10周的多模式体重控制项目。在基线、第4周、第8周、第10周(干预结束时)、第12周、第24周和第48周记录患者的体重。次要指标包括血糖水平、胆固醇水平、甘油三酯水平、生活质量和心理健康。

结果

对于完成体重控制项目的患者,干预结束时平均体重减轻2.1千克,6个月内减轻3.7千克,12个月内减轻2.7千克。在第10周、第24周和第48周,平均体重指数分别下降了0.8、1.5和1.1,均具有统计学意义。

结论

为期10周的体重控制项目对于患有精神分裂症或分裂情感性障碍的肥胖患者在减轻体重方面是有效的,体重减轻效果可持续长达6个月,在某些情况下可持续长达12个月。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验